Head to Head Survey: Miragen Therapeutics (MGEN) versus Cannabis Science (CBIS)
Miragen Therapeutics (NASDAQ: MGEN) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Valuation & Earnings
This table compares Miragen Therapeutics and Cannabis Science’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Miragen Therapeutics||$3.34 million||53.30||-$12.67 million||($8.93)||-0.89|
Insider & Institutional Ownership
22.6% of Miragen Therapeutics shares are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Miragen Therapeutics and Cannabis Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for Miragen Therapeutics and Cannabis Science, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Miragen Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 200.75%. Given Miragen Therapeutics’ higher probable upside, equities analysts clearly believe Miragen Therapeutics is more favorable than Cannabis Science.
Risk and Volatility
Miragen Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -3.62, suggesting that its stock price is 462% less volatile than the S&P 500.
Miragen Therapeutics beats Cannabis Science on 8 of the 9 factors compared between the two stocks.
Miragen Therapeutics Company Profile
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Cannabis Science Company Profile
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.